MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.

HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.

Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care.

Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution.

The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.

Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort.

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.

Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.

How and When to Manage Ruxolitinib Failure in Myelofibrosis.

Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.